Last reviewed · How we verify

Pombiliti — Competitive Intelligence Brief

Pombiliti (CIPAGLUCOSIDASE ALFA) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Cation-independent mannose-6-phosphate receptor Metabolic Enzyme Live · refreshed every 30 min

Target snapshot

Pombiliti (CIPAGLUCOSIDASE ALFA) — Amicus Therapeutics Europe Limited. Pombiliti works by replacing the deficient acid alpha-glucosidase enzyme in patients with Late-onset Pompe disease.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pombiliti TARGET CIPAGLUCOSIDASE ALFA Amicus Therapeutics Europe Limited marketed Cation-independent mannose-6-phosphate receptor 2023-01-01
POMBILITI CIPAGLUCOSIDASE ALFA-ATGA AMICUS THERAP US marketed Cation-independent mannose-6-phosphate receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pombiliti — Competitive Intelligence Brief. https://druglandscape.com/ci/cipaglucosidase-alfa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: